1	Ranked severe maternal morbidity index for population-level surveillance at delivery
2	hospitalization based on hospital discharge data
3	
4	Elena V. Kuklina <sup>1</sup> , Alexander C. Ewing <sup>1</sup> , Glen A. Satten <sup>1</sup> , William M. Callaghan <sup>1</sup> , David A.
5	Goodman <sup>1</sup> , Cynthia D. Ferre <sup>1</sup> , Jean Y. Ko <sup>1,2</sup> , Lindsay S. Womack, PhD <sup>1,2*</sup> , Romeo R. Galang <sup>1</sup> ,
6	Charlan D. Kroelinger <sup>1</sup>
7	
8	<sup>1</sup> Division of Reproductive Health, National Center for Chronic Disease Prevention and Health
9	Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of
10	America
11	<sup>2</sup> United States Public Health Service, Commissioned Corps, Rockville, Maryland, United States
12	of America
13	
14	* Corresponding author
15	LWomack@cdc.gov (LSW)
16	
17	Disclaimer:
18	The findings and conclusions in this paper are those of the authors and do not necessarily
19	represent the official position of the Centers for Disease Control and Prevention.
20	

# 21 Abstract

22	Background: Severe maternal morbidity (SMM) is broadly defined as an unexpected and
23	potentially life-threatening event associated with labor and delivery. The Centers for Disease
24	Control and Prevention (CDC) produced 21 different indicators based on International
25	Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) hospital diagnostic
26	and procedure codes to identify cases of SMM.
27	<b>Objectives:</b> To examine existing SMM indicators and determine which indicators identified the
28	most in-hospital mortality at delivery hospitalization.
29	Methods: Data from the 1993–2015 and 2017–2019 Healthcare Cost and Utilization Project's
30	National Inpatient Sample were used to report SMM indicator-specific prevalences, in-hospital
31	mortality rates, and population attributable fractions (PAF) of mortality. We hierarchically
32	ranked indicators by their overall PAF of in-hospital mortality. Predictive modeling determined
33	if SMM prevalence remained comparable after transition to ICD-10-CM coding.
34	<b>Results:</b> The study population consisted of 18,198,934 hospitalizations representing 87,864,173
35	US delivery hospitalizations. The 15 top ranked indicators identified 80% of in-hospital
36	mortality; the proportion identified by the remaining indicators was negligible (2%). The top 15
37	indicators were: restoration of cardiac rhythm; cardiac arrest; mechanical ventilation;
38	tracheostomy; amniotic fluid embolism; aneurysm; acute respiratory distress syndrome; acute
39	myocardial infarction; shock; thromboembolism, pulmonary embolism; cerebrovascular
40	disorders; sepsis; both DIC and blood transfusion; acute renal failure; and hysterectomy. The
41	overall prevalence of the top 15 ranked SMM indicators (~22,000 SMM cases per year) was
42	comparable after transition to ICD-10-CM coding.

- 43 **Conclusions:** We determined the 15 indicators that identified the most in-hospital mortality at
- 44 delivery hospitalization in the US. Continued testing of SMM indicators can improve
- 45 measurement and surveillance of the most severe maternal complications at the population level.

## 46 Introduction

47 Severe maternal morbidity (SMM) is broadly defined as an unexpected and potentially 48 life-threatening event associated with labor and delivery [1]. SMM is associated with prolonged 49 [2] and increased costs of hospital stay [3], fetal deaths [4], preterm deliveries [5], and long-term 50 consequences for maternal physical and mental health [1,6,7]. At the population level, SMM 51 surveillance is commonly conducted using administrative hospital discharge data based on 52 International Classification of Diseases (ICD) codes [8]. The Centers for Disease Control and 53 Prevention (CDC) produced an index consisting of 21 indicators based on ICD diagnostic and 54 procedure codes to identify SMM cases [9]. Combining the 21 indicators into a single index 55 enables population-level surveillance of life-threatening events, interventions, and organ failure 56 types given analyzing individual indicators may not be feasible due to rare occurrence at delivery 57 hospitalization. Research shows combining multiple indicators into a single index offers 58 consistency in monitoring trends and is more straightforward to both communicate and 59 understand than are individual indicators described in complex medical terminology [10]. 60 However, some individual SMM indicators have measurement concerns or may lack 61 specificity for disease severity. Numerous studies have assessed measurement issues for 62 individual SMM indicators (e.g., blood transfusion, disseminated intravascular coagulation 63 [DIC], eclampsia) [11–13]. For example, blood transfusion and DIC are the most prevalent SMM 64 indicators in the US [9], yet these indicators have low sensitivity (65% and 22%, respectively) [13] in validation studies using medical records and a substantial proportion of hospital discharge 65 records with blood transfusion and DIC do not reflect severe morbidity [11,13]. Similarly, a 66 67 previous study has reported a low positive predictive value (41.7%) for ICD codes associated

68	with eclampsia [14]. Composite measurements, like the SMM index, only perform well if
69	individual indicators in the index meet specific criteria (reliability, validity, feasibility) [10].
70	To determine how well individual indicators perform in identifying severe morbidity, our
71	study ranks individual indicators according to how they identify in-hospital mortality, a well-
72	accepted measure of severity [2]. We rank each indicator hierarchically according to its
73	contribution to the overall SMM index using its population attributable fraction (PAF) of in-
74	hospital mortality and a novel signal-to-noise ratio (SNR), that compares the level of a signal
75	(measurement) to the level of background noise (variability) [15]. To assess whether patterns and
76	prevalence of SMM indices remained consistent across the transition from ICD-9 to ICD-10
77	coding, we estimated predicted prevalence for 2017–2019 using ICD-9 coded data and compared
78	these to the observed prevalence using ICD-10 coded data.

79

## 80 Methods

81 We used the 1993–2019 National Inpatient Sample (NIS), the largest database of all-82 payer hospital discharge records in the US [16]. The NIS is a uniform, standardized dataset based 83 on state in-patient data that are contributed to the Healthcare Cost and Utilization Project that is 84 weighted by the Agency for Healthcare Research and Quality (AHRQ) to produce nationally 85 representative estimates.

The NIS contains up to 40 diagnosis and 25 procedure codes per discharge including
Diagnosis-Related Group (DRG) codes, as well as hospitalization characteristics, including
patient demographics, admission source, discharge disposition, length of stay, and hospital
charges. In-hospital mortality was identified using the variable "died during hospitalization." To
ensure comparability of data across all years, AHRQ created trend weights for 1993–2011 that

91	are consistent with the 2012 and later redesigned NIS datasets [17]. The cross-sectional nature of
92	NIS prevented identification of multiple delivery hospitalizations for the same woman; thus, the
93	unit of analysis in this study was the delivery hospitalization, not the individual.
94	Due to the transition from ICD-9 to ICD-10 coding on October 2015, we first limited our
95	analysis to delivery hospitalizations between January 1993 and September 2015 for
96	comparability of codes across years and to obtain a sufficient sample size to produce reliable
97	estimates of SMM and death, since these are rare events. We identified delivery hospitalizations
98	using a previously described algorithm [18].

99

### 100 SMM indicators

101 The starting point for indicator selection was the 21 current SMM indicators identified by 102 CDC; however, as discussed previously, there are measurement concerns for DIC, blood 103 transfusion, and eclampsia [11]. We recoded these three indicators having measurement 104 concerns. We recoded the data into three mutually exclusive indicators for DIC and blood 105 transfusion: 1) a combination indicator, including codes for both DIC and blood transfusion; 2) 106 an indicator including DIC codes but no blood transfusion codes; and 3) an indicator including 107 blood transfusion codes but no DIC codes. The eclampsia indicator was recoded into a new 108 indicator for severe types of hypertensive disorders of pregnancy and included severe pre-109 eclampsia, HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count), or 110 eclampsia, consistent with the latest revision of the Canadian SMM index [2]. In summary, we 111 removed the three current indicators with measurement issues (DIC; blood transfusion; 112 eclampsia), and added four recoded indicators (DIC and blood transfusion; DIC without 113 transfusion; transfusion only; severe pre-eclampsia, HELLP syndrome, or eclampsia), resulting

in 22 SMM indicators for ranking according to how each indicator identifies in-hospitalmortality.

116

### 117 Statistical analysis

We calculated the prevalence, in-hospital mortality rate (%) and relative risk (RR) for 118 119 each of the 25 SMM indicators (21 current indicators and four recoded indicators). Next, we 120 calculated the PAF for the in-hospital mortality rate of each indicator [19]. PAFs for all SMM 121 indicators were calculated using the formula  $p_d$  ((RR-1)/RR) where  $p_d$  is the proportion with the 122 indicator among all hospital discharge records with in-hospital death and RR is the estimated 123 relative risk of indicator-specific in-hospital death [19]. The estimated RR associated with a 124 specific indicator was obtained from log-linear models, adjusting for year, payer, age, race [20], 125 hospital region, hospital location (urban, rural and teaching), and all other SMM indicators. 126 Missing was treated as a separate category when analyzing data on race. Covariates were 127 selected a priori, based on the literature and clinical significance. Some indicators had a large 128 PAF due to high prevalence, but a low in-hospital mortality rate indicating these indicators may 129 not represent severe complications. To address this, we developed a SNR [15] formula: the PAF 130 for an indicator (signal) divided by the increase in standard deviation (noise) in the entire ranked 131 SMM index that occurs when the indicator is included in the model compared to when it is not 132 included (indicator-specific SNR equation, S1 Appendix). A higher SNR value suggests that an 133 indicator's higher PAF is due to a higher mortality rate rather than a higher prevalence in the 134 population.

We used a hierarchical, iterative process to rank the 22 indicators (21 current indicators,
removing three indicators with measurement issues and adding four recoded indicators), ordering

137 by the highest SNR. This process included: 1) calculating the SNR for each indicator and ranking 138 the indicators by this value; 2) selecting the indicator with the highest SNR; 3) removing all as-139 yet-unselected indicators from a delivery hospitalization if that hospitalization also had the 140 selected indicator. This final step in an iteration forces the selected indicator to be mutually 141 exclusive of the remaining indicators, regardless of whether the hospitalization included other 142 co-occurring indicators. This step is appropriate for our application, as we only wanted to rank 143 indicators by their capacity to identify deaths not already identified by indicators having higher 144 ranking. We repeated this iterative, ranking process until all 22 indicators were selected and 145 mutually exclusive.

When an indicator was selected and made mutually exclusive, the resulting PAF was recalculated and designated as the *hierarchical* PAF (hPAF) and was held constant for subsequent iterations. Because the indicator conditions were made mutually exclusive, the cumulative hPAF comprised of the ranked indicators was then calculated by summing the hPAF values. This approach to indicator selection allowed us to rank the indicators in order of importance in identifying in-hospital mortality.

152 We then calculated the annual SMM prevalence per 10,000 delivery hospitalizations 153 based on (1) all 21 current SMM indicators identified by CDC, (2) 20 current SMM indicators 154 (excluding blood transfusion), (3) blood transfusion alone, and (4) the top 15 ranked SMM 155 indicators that identified the most in-hospital mortality. To assess whether patterns and 156 prevalence using the top ranked SMM indicators remained consistent across the ICD coding 157 transition, we estimated predicted prevalences for 2017–2019 using ICD-9 coded data and 158 compared these to the observed prevalence calculated using ICD-10 coded data. The predicted 159 estimates and 95% confidence intervals were based on logistic regression models using NIS data

168	Ethics approval
167	
166	using SAS 9.4 (SAS Institute Inc).
165	11.0.3, using NIS-provided weights and design variables. All other analyses were conducted
164	All national estimates and 95% confidence intervals were produced using SUDAAN
163	Percent differences were calculated to compare predicted values with observed values.
162	2016 as this was the first year after the ICD transition and coding practices were in transition.
161	prevalence of the individual top ranked SMM indicators as outcomes. We excluded data from
160	from 2010–2015, preceding the ICD coding transition, with the year as a covariate and the

Because the NIS are de-identified data, this study did not require approval by aninstitutional review board at the CDC.

171

## 172 **Results**

173 The study population consisted of 18,198,934 hospitalizations representing 87,864,173 174 US delivery hospitalizations of women ages 12–55 years (1993–2015; S1 Table). There were 0.8 175 in-hospital deaths per 10,000 delivery hospitalizations (n = 6,685). The indicator-specific 176 prevalence, in-hospital mortality rate, PAF, and SNR for the 21 current SMM indicators and the 177 four recoded indicators (n=25 indicators) are summarized in Table 1. The recoded indicator for 178 severe pre-eclampsia, HELLP syndrome, or eclampsia was most common (160.9 per 10,000 179 delivery hospitalizations). However, its in-hospital mortality rate (0.1%) was the lowest of all 180 indicators and 10 other indicators had a higher PAF (>9.8). Blood transfusion and the recoded 181 blood transfusion without DIC were the second and third most common indicators at 70.1 and 182 65.6 per 10,000 delivery hospitalizations, respectively, but had low mortality rates (0.3% and

0.2%). Indicator-specific mortality rates were greatest for restoration of cardiac rhythm (37.1%), 183 184 cardiac arrest (36.5%), and amniotic fluid embolism (15.9%). 185 Table 2 shows the order of the indicators established by our iterative process with hPAF 186 and SNR values, excluding the three current indicators with measurement issues and adding four 187 recoded indicators (n=22 indicators). The indicators with the three highest hPAFs, mechanical 188 ventilation (29.4%), restoration of cardiac rhythm (25.2%), and cardiac arrest (14.4%), were 189 ranked third, first and second, respectively. Cardiac arrest had the highest SNR (69.4). 190 Among all delivery hospitalizations, the 22 SMM indicators identified 82% of in-hospital 191 mortality. The top three ranked indicators (restoration of cardiac rhythm, cardiac arrest, 192 mechanical ventilation) identified approximately 69% of in-hospital mortality. The top 15 ranked 193 SMM indicators accounted for 80% of in-hospital mortality, while the bottom seven indicators 194 together only identified an additional 2% of in-hospital mortality. Therefore, the top 15 195 indicators were combined into a ranked index for further analysis. 196 From 1993–2015, the overall SMM prevalence using the combined 21 current SMM 197 indicators increased 143%, from 72.9 to 177.1 per 10,000 delivery hospitalizations (Fig 1). 198 During this time, the prevalence of blood transfusion increased by almost 400%, driving a large 199 portion of the increase in prevalence. The SMM prevalence of the 20 current SMM indicators, 200 excluding blood transfusion, increased by 37% from 1993–2015. By contrast, the prevalence of 201 the top 15 ranked SMM indicators increased by 79%, from 23.4 to 41.8 per 10,000 delivery 202 hospitalizations from 1993–2015. 203 The observed cumulative SMM prevalence estimates are within the predicted 95% 204 confidence intervals in 2017 and 2019 among delivery hospitalizations, but fell slightly outside

in 2018 (Table 3, Fig 1). Eleven of the 15 indicators had observed prevalences within the

predicted 95% confidence interval in 2017 and 2019, while nine did in 2018. In 2019, the
estimated SMM prevalence using the top 15 ranked indicators that identified the most in-hospital
mortality was 55 per 10,000 delivery hospitalizations (approximately SMM 21,800 [range
20,800 to 22,900] cases per year assuming 4 million delivery hospitalizations per year
nationally).

211

## 212 **Discussion**

213 Among approximately 88 million delivery hospitalizations, 15 SMM indicators identified 214 80% of in-hospital mortality in 1993–2015. The overall prevalence of this 15-indicator ranked 215 SMM index increased by approximately 80% from 1993–2015. In contrast, while the prevalence 216 of the current 20 SMM indicators, excluding blood transfusion, only increased 37% from 1993-217 2015. Using predicted estimates for 2017–2019, the prevalence of this 15-indicator ranked SMM 218 index is 54.6 per 10,000 delivery hospitalizations or approximately 22,000 SMM cases per year. 219 A major strength of this study is the use of NIS, a large, representative national all-payer 220 database widely used in the US to provide generalizable estimates and trends. NIS provided a 221 unique opportunity to determine which SMM indicators, though rare outcomes, identified the 222 most in-hospital mortality at delivery hospitalization. Our study has several limitations. First, the 223 SMM indicators include both diagnosis and procedure-based indicators from administrative data, 224 for which coding rules change over time. Procedure-based indicators may be a proxy for multiple 225 diagnosis-based indicators. For example, ventilation may be an indirect indicator of acute 226 respiratory distress syndrome, pulmonary edema, and/or pulmonary embolism. Second, we used 227 pre-defined conditions or procedures to ascertain SMM indicators from the hospital discharge 228 records. The indicators identified 82% of in-hospital mortality, therefore approximately 18% is

attributable to conditions not identified by these analyses. Conditions not included as indicators 229 230 of severe morbidity that identify in-hospital mortality include those that clinicians encounter in 231 the Intensive Care Unit (ICU; e.g., motor vehicle crashes, poisoning, suicides, malignancies). 232 The NIS does not include ICU admission status for all reporting states.[16] Additionally, the 233 SMM indicators do not capture information on comorbidities such as mental health conditions or 234 substance use disorders which may also contribute to in-hospital mortality. Third, our study only 235 examines in-hospital mortality at delivery hospitalization and does not look at antepartum or 236 postpartum hospitalizations. This study does not capture the full spectrum of pregnancy related 237 deaths that occur during pregnancy or up to one year postpartum. Fourth, we did not incorporate 238 length of stay (LOS) in our algorithm. The SMM indicators with and without LOS 239 considerations demonstrated excellent reliability (kappa statistic=0.927) in a study from 240 California [21]. Hence, its inclusion may add methodological complexity and may not contribute 241 to meaningful interpretation of the association between SMM and in-hospital mortality. Fifth, the 242 quality of documentation by physicians, coders' training, and ongoing initiatives may affect 243 coding accuracy [22]. Several validity studies reported high to moderate specificity but low 244 sensitivity for some ICD-9 codes for SMM [11-13]. Although limited studies on the validity of 245 ICD-10 codes are available, the sensitivity of these codes may be lower than for ICD-9 codes 246 [13], though it may vary by indicator. Sixth, we were limited in examining pulmonary edema 247 and acute congestive heart failure separately due to interchangeable coding practices for 248 pulmonary edema and heart failure [23]. Pulmonary edema is labeled as a left ventricular failure 249 in the coding manual and described as a left ventricular failure or heart failure in the medical 250 chart [23], though ambiguity of medical diagnoses like this are inherent when using 251 administrative data sets for analyses rather than individual medical records. Finally, we

combined the top 15 SMM indicators into a ranked index for further analysis because these
indicators identified 80% of in-hospital mortality and the remaining indicators only identified
2%; however, this threshold of 15 was arbitrary.

255 Our study offers an index for SMM population-level surveillance. While there are 256 limitations to using administrative data to identify SMM, the ranked SMM index provides a 257 measurement that is associated with the most severe outcome, in-hospital mortality, and can be 258 used as a marker for maternal health.

The top three ranked indicators (restoration of cardiac rhythm, cardiac arrest, mechanical ventilation), all markers of acute cardiac and respiratory compromise, identified approximately 69% of in-hospital mortality. While cardiac arrest may result from a variety of cardiovascular and non-cardiovascular conditions, cardiovascular conditions are among the leading causes of maternal death [24]. This highlights the importance of rapid response teams, checklists, huddles, and debriefs to ensure successful and prompt resuscitation [25,26].

265 The most prevalent indicators were the recoded severe type of hypertension of pregnancy 266 indicator, the current blood transfusion indicator, and the recoded blood transfusion without DIC 267 indicator; however, none of these indicators ranked among the top 15 indicators. Hypertensive 268 disorders in pregnancy and postpartum hemorrhage are significant contributors to maternal 269 morbidity and mortality and have increased in prevalence over the last two decades [24,27]. In 270 our analysis, we recoded the eclampsia indicator to include severe pre-eclampsia and HELLP 271 syndrome in order to capture a broader spectrum of hypertensive disorders in pregnancy. While 272 the severe pre-eclampsia, HELLP syndrome, or eclampsia indicator was last on our mutually 273 exclusive, ranked SMM index, it is possible that an SMM code indicating a consequence of 274 severe pre-eclampsia, HELLP syndrome, or eclampsia that is more strongly associated with in-

275 hospital mortality (e.g., a puerperal cerebrovascular disorder; mechanical ventilation) would also 276 be present. This would produce a lower hierarchical ranking of this indicator individually. The 277 current blood transfusion indicator and the recoded blood transfusion without DIC indicator were 278 the second and third most prevalent indicators. Obstetric transfusions are primarily associated 279 with postpartum hemorrhage, and we sought to capture severe cases of postpartum hemorrhage 280 by recoding the blood transfusion and DIC indicators. The NIS data do not quantify transfusion 281 of blood products in units which might serve as a proxy for severity [28]. However, hospital 282 discharge records with severe blood loss resulting in hemorrhagic shock are expected to have 283 ICD codes for blood transfusion and multiple organ failure, including DIC. Thus, most 284 hospitalizations with severe hemorrhage in our study should be captured by indicators of organ 285 failure. The recoded indicator for both DIC and blood transfusion was among the 15 top ranked 286 indicators. By making indicators mutually exclusive during the ranking process, we identified 287 how many additional SMM deaths an indicator would capture, accounting for indicators already 288 ranked. This process does not account for the true burden of the condition which informs 289 population-based initiatives for prevention through organizations such as perinatal quality 290 collaboratives [29].

Our methodology allowed the ranking of rare indicators with high in-hospital mortality and requires further testing. The strength and quality of evidence generated by its use could provide the basis for further refinement of SMM indicators, increasing potential applicability. Validation studies of the indicators used for the ranked SMM index are needed and may inform index utility.

Our results have important public health and surveillance implications. While this ranked
 SMM index results in a lower rate and total number of SMM cases compared with estimates of

298 SMM using the combined 21 current indicators, it directly addresses the criticism of the 299 combined 21 current SMM indicators: a lack of specificity for disease severity [11,21]. While 300 "severe" is difficult to define, linking diagnosis and procedure codes to in-hospital mortality 301 underscores that selected conditions and events precede the most severe event, death. However, a 302 ranking of indicators for the purpose of determining how many deaths could be prevented by 303 sequentially eliminating indicators would need to use a different definition of PAF than we used 304 (e.g., Benichou 2007) [30]; in particular, our hPAF is not appropriate for this purpose. 305 The ranked SMM index is for surveillance at the population level and was not developed 306 for individual facility reviews [8]. Criteria for facility review of SMM are outlined by clinical 307 organizations such as the American College of Obstetricians and Gynecologists and the Society 308 for Maternal and Fetal Medicine [31]. The indicators included in the ranked SMM index could 309 facilitate further refinement of SMM indicators for other uses (e.g., facility-based identification 310 and review of SMM) and improve overall utility.

311 The ranked SMM index is unsuitable for comparison of individual health care institutions 312 for multiple reasons. Health care institutions have access to the medical record and detailed and 313 reliable data on comorbidities and severity, unavailable in the NIS, yielding more accurate, 314 informative, and comparable case results. Comorbid conditions are strong predictors of overall 315 SMM [32], but comorbid conditions are under-reported in hospital discharge data [33], with 316 limited studies of reliability of ICD codes among hospitals [34], especially among delivery 317 hospitalizations. The NIS data lack information on prenatal care and antepartum risk factors that 318 are important determinants of SMM [35]. These factors are not considered in this ranked SMM 319 index to adjust for differences in case-mix among institutions. Facilities with higher levels of 320 maternal care are expected to have more high-risk deliveries and may have higher SMM rates

321 compared with lower-level facilities [32]. Our approach of creating mutually exclusive indicators 322 through iterative ranking may not be appropriate for care management goals in individual health 323 care institutions. For instance, the risk of in-hospital death and thus, the condition severity and 324 complexity of clinical management, increases with the growing number of SMM indicators [36]. 325 Clinical reviews allow identification of preventable causes of SMM including determinants of 326 clinical practices associated with SMM [31]. Only clinical reviews can guide design of hospital-327 level interventions and quality improvement initiatives to reduce SMM. A recent study of ICD-328 10 coding for blood transfusion, DIC, and acute renal failure confirmed wide variability of code 329 sensitivity among hospitals in administrative discharge data and cautioned against using this type 330 of data to compare inter-hospital safety and quality improvement initiatives at the facility level 331 [13].

332

### 333 Conclusions

334 This study offers an index for reporting severe conditions using 15 indicators that identify 335 4 in 5 in-hospital deaths at delivery hospitalization. These indicators, when considered together, 336 yield an index for population-level SMM surveillance based on in-hospital mortality. SMM 337 surveillance is a promising method to further the understanding of maternity care and ultimately 338 improve it [37]. Surveillance quality can be improved by reviewing medical records and 339 corresponding ICD-10 codes to determine validity. Since a substantial proportion of pregnancy-340 related deaths and serious pregnancy-related complications occur outside of the delivery 341 hospitalization, additional indices for antenatal and postpartum periods are needed [24]. Our 342 findings underscore the need for continued testing of SMM indicators to refine metrics that 343 provide simplified measurement of severe obstetric complications at the population level.

344

## 345 **References**

346	1.	Lewkowitz AK,	Rosenbloom JI,	Keller M,	López JD,	Macones GA,	Olsen MA, et al
-----	----	---------------	----------------	-----------	-----------	-------------	-----------------

- 347 Association between severe maternal morbidity and psychiatric illness within 1 Year of
- 348 hospital discharge after delivery. Obstet Gynecol. 2019;134(4): 695–707.
- doi:10.1097/AOG.0000000003434
- 2. Dzakpasu S, Deb-Rinker P, Arbour L, Darling EK, Kramer MS, Liu S, et al. Severe
- 351 maternal morbidity surveillance: Monitoring pregnant women at high risk for prolonged
- hospitalisation and death. Paediatr Perinat Epidemiol. 2020;34(4): 427–439.
- 353 doi:10.1111/PPE.12574
- 354 3. Debbink MP, Metz TD, Nelson RE, Janes SE, Kroes A, Begaye LJ, et al. Directly
- 355 measured costs of severe Maternal morbidity events during delivery admission compared
- 356 with uncomplicated deliveries. Am J Perinatol. 2022;39(6): 567–576. doi:10.1055/S-0041-
- 357 1740237
- 4. Wall-Wieler E, Carmichael SL, Gibbs RS, Lyell DJ, Girsen AI, El-Sayed YY, et al.
- 359 Severe maternal morbidity among stillbirth and live birth deliveries in California. Obstet

360 Gynecol. 2019;134(2): 310–317. doi:10.1097/AOG.00000000003370

- 361 5. Kilpatrick SJ, Abreo A, Gould J, Greene N, Main EK. Confirmed severe maternal
- 362 morbidity is associated with high rate of preterm delivery. Am J Obstet Gynecol.
- 363 2016;215(2): 233.e1-233.e2337. doi:10.1016/J.AJOG.2016.02.026
- 6. Fenech G, Thomson G. Tormented by ghosts from their past': a meta-synthesis to explore
- 365 the psychosocial implications of a traumatic birth on maternal well-being. Midwifery.
- 366 2014;30(2): 185–193. doi:10.1016/J.MIDW.2013.12.004

367	7.	Wall-Wieler E, Carmichael SL, Urquia ML, Liu C, Hjern A. Severe maternal morbidity
368		and postpartum mental health-related outcomes in Sweden: A population-based matched-
369		cohort study. Arch Womens Ment Health. 2019;22(4): 519-526. doi:10.1007/S00737-018-
370		0917-Z
371	8.	Kuklina EV, Goodman DA. Severe maternal or near miss morbidity: Implications for
372		public health surveillance and clinical audit. Clin Obstet Gynecol. 2018;61(2): 307-318.
373		doi:10.1097/GRF.000000000000375
374	9.	Callaghan WM, Creanga AA, Kuklina E V. Severe maternal morbidity among delivery
375		and postpartum hospitalizations in the United States. Obstet Gynecol. 2012;120(5): 1029-
376		1036. doi:10.1097/AOG.0B013E31826D60C5
377	10.	Shwartz M, Restuccia JD, Rosen AK. Composite measures of health care provider
378		performance: A description of approaches. Milbank Q. 2015;93(4): 788-825.
379		doi:10.1111/1468-0009.12165
380	11.	Main EK, Abreo A, McNulty J, Gilbert W, McNally C, Poeltler D, et al. Measuring severe
381		maternal morbidity: validation of potential measures. Am J Obstet Gynecol. 2016;214(5):
382		643.e1-643.e10. doi:10.1016/J.AJOG.2015.11.004
383	12.	Sigakis MJG, Leffert LR, Mirzakhani H, Sharawi N, Rajala B, Callaghan WM, et al. The
384		validity of discharge billing codes reflecting severe maternal morbidity. Anesth Analg.
385		2016;123(3): 731–738. doi:10.1213/ANE.00000000001436
386	13.	Friedman AM, Oberhardt M, Sheen JJ, Kessler A, Vawdrey D, Green R, et al.
387		Measurement of hemorrhage-related severe maternal morbidity with billing versus
388		electronic medical record data. J Matern Fetal Neonatal Med. 2022;35(12):2234-2240.
389		doi:10.1080/14767058.2020.1783229

- 390 14. Geller SE, Ahmed S, Brown ML, Cox SM, Rosenberg D, Kilpatrick SJ. International
- 391 classification of diseases-9th revision coding for preeclampsia: How accurate is it? Am J
- 392 Obstet Gynecol. 2004;190(6): 1629–1633. doi:10.1016/j.ajog.2004.03.061
- 393 15. George F, Kibria BMG. Confidence intervals for estimating the population signal-to-noise
- 394 ratio: a simulation study. J Appl Stat. 2012;39(6): 1225–1240.
- 395 doi:10.1080/02664763.2011.644527
- 396 16. Healthcare Cost and Utilization Project (HCUP). Introduction to the HCUP National

397 Inpatient Sample (NIS), 2015. Available: https://www.hcup-

- 398 us.ahrq.gov/db/nation/nis/NIS\_Introduction\_2015.jsp [Accessed 11 May 2023].
- 399 17. Healthcare Cost and Utilization Project (HCUP). Trend weights for HCUP NIS data.
- 400 Available from: https://www.hcup-us.ahrq.gov/db/nation/nis/trendwghts.jsp [Accessed 11
  401 May 2023].
- 402 18. Kuklina E V., Whiteman MK, Hillis SD, Jamieson DJ, Meikle SF, Posner SF, et al. An
- 403 enhanced method for identifying obstetric deliveries: implications for estimating maternal
- 404 morbidity. Matern Child Health J. 2008;12(4): 469–477. doi:10.1007/S10995-007-0256-6
- 405 19. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions.
- 406 [published correction appears in Am J Public Health. 2008 Dec;98(12):2119]. Am J Public
- 407 Health. 1998;88(1):15-19. doi:10.2105/ajph.88.1.15
- 408 20. Healthcare Cost and Utilization Project (HCUP). HCUP NIS Description of Data
- 409 Elements. Available from: https://www.hcup-us.ahrq.gov/db/vars/race/nisnote.jsp
- 410 [Accessed 11 May 2023].
- 411 21. Snowden JM, Lyndon A, Kan P, El Ayadi A, Main E, Carmichael SL. Severe maternal
- 412 morbidity: A comparison of definitions and data sources. Am J Epidemiol. 2021;190(9):

- 413 1890–1897. doi:10.1093/AJE/KWAB077
- 414 22. Konrad R, Zhang W, Bjarndóttir M, Proaño R. Key considerations when using health
- 415 insurance claims data in advanced data analyses: an experience report. Heal Syst
- 416 (Basingstoke, England). 2019;9(4): 317–325. doi:10.1080/20476965.2019.1581433
- 417 23. Quach S, Blais C, Quan H. Administrative data have high variation in validity for
- 418 recording heart failure. Can J Cardiol. 2010;26(8):306–312. doi:10.1016/S0828-
- 419 282X(10)70438-4
- 420 24. Petersen EE, Davis NL, Goodman D, Cox S, Mayes N, Johnston E, et al. Vital Signs:
- 421 Pregnancy-related deaths, United States, 2011-2015, and strategies for prevention, 13
- 422 States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2019;68(18):423–429.
- 423 doi:10.15585/MMWR.MM6818E1
- 424 25. Solomon RS, Corwin GS, Barclay DC, Quddusi SF, Dannenberg MD. Effectiveness of
- 425 rapid response teams on rates of in-hospital cardiopulmonary arrest and mortality: A
- 426 systematic review and meta-analysis. J Hosp Med. 2016;11(6): 438–445.
- 427 doi:10.1002/JHM.2554
- 428 26. Trejo FE, Igel CM, Chuang M, Bajaj K, Bernstein PS. Checklists, huddles, and debriefs:
- 429 Critical tools to improve team performance in obstetrics. Clin Obstet Gynecol.
- 430 2019;62(3): 518–527. doi:10.1097/GRF.00000000000464
- 431 27. Ford ND, Cox S, Ko JY, Ouyang L, Romero L, Colarusso T, et al. Hypertensive disorders
- 432 in pregnancy and mortality at delivery hospitalization United States, 2017-2019.
- 433 MMWR Morb Mortal Wkly Rep. 2022;71(17): 585–591.
- 434 doi:10.15585/MMWR.MM7117A1
- 435 28. Mhyre JM, Shilkrut A, Kuklina EV, Callaghan WM, Creanga AA, Kaminsky S, et al.

436	Massive bloo	d transfusion	during	hospitalization	for delivery	v in New	York State.	1998-

- 437 2007. Obstet Gynecol. 2013;122(6): 1288–1294. doi:10.1097/AOG.000000000000021
- 438 29. Centers for Disease Control and Prevention. Perinatal Quality Collaboratives. Available
- 439 from: https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pqc.htm [Accessed 11
- 440 May 2023].
- 441 30. Benichou J. Biostatistics and epidemiology: measuring the risk attributable to an
- 442 environmental or genetic factor. C R Biol. 2007;330(4): 281–298.
- 443 doi:10.1016/J.CRVI.2007.02.015
- 444 31. Obstetric Care Consensus No. 5. Severe maternal morbidity: Screening and review. Obstet

445 Gynecol. 2016;128(3): e54–e60. doi:10.1097/AOG.00000000001642

- 446 32. Main EK, Leonard SA, Menard MK. Association of maternal comorbidity with severe
- 447 maternal morbidity: A cohort study of California mothers delivering between 1997 and

448 2014. Ann Intern Med. 2020;173(11 Suppl): S11–S18. doi:10.7326/M19-3253

- 449 33. Salemi JL, Hansen MA, Modak S, Matas JL, Germanos GJ, Raza SA, et al. Estimating the
- 450 obstetric co-morbidity burden using administrative data: The impact of the pregnancy-
- 451 related assessment window. Paediatr Perinat Epidemiol. 2020;34(4): 440–451.
- 452 doi:10.1111/PPE.12593
- 453 34. McPheeters ML, Sathe NA, Jerome RN, Carnahan RM. Methods for systematic reviews
- 454 of administrative database studies capturing health outcomes of interest. Vaccine. 2013;31
- 455 Suppl 10:K2–K6. doi:10.1016/J.VACCINE.2013.06.048
- 456 35. Howell EA. Reducing disparities in severe maternal morbidity and mortality. Clin Obstet
- 457 Gynecol. 2018;61(2): 387–399. doi:10.1097/GRF.00000000000349
- 458 36. Ray JG, Park AL, Dzakpasu S, Dayan N, Deb-Rinker P, Luo W, et al. Prevalence of

- 459 severe maternal morbidity and factors associated with maternal mortality in Ontario,
- 460 Canada. JAMA Netw Open. 2018;1(7):e184571.
- doi:10.1001/JAMANETWORKOPEN.2018.4571
- 462 37. Callaghan WM. Identifying cases of severe maternal morbidity: Moving beyond the
- 463 delivery hospitalization. Obstet Gynecol. 2022;139(2): 163–164.
- 464 doi:10.1097/AOG.00000000004665

	467	Table 1. Prevalence, in-hospital morta	lity, population attributable fraction	on (PAF), and signal-to-noise ratio (SNR) for sev	vere
--	-----	--	--	---	------

468 maternal morbidity indicators (SMM), Nationwide Inpatient Sample, 1993–2015 (weighted sample = 87,864,173, unweighted

469 **sample = 18,198,934**).

	Prevalence among delivery hospitalizations		In-hos	pital mortality	PAF <sup>a</sup>	SNR
						b
SMM Indicators	n <sup>c</sup>	Per 10,000 deliveries (95% CI <sup>d</sup> )	n	% (95% CI <sup>d</sup> )	%	
Severe pre-eclampsia, HELLP <sup>d</sup> syndrome, or	1,414,150	160.9 (155.8, 165.9)	1,379	0.1 (0.1, 0.1)	9.8	0.8
eclampsia <sup>e</sup>						
Blood transfusion	615,984	70.1 (67.7, 72.5)	2,143	0.3 (0.3, 0.4)	21.4	2.6
Blood transfusion without DIC <sup>d,e</sup>	576,929	65.6 (63.4, 67.9)	1,065	0.2 (0.2, 0.2)	13.9	1.7
DIC	209,700	23.9 (23.0, 24.8)	2,029	1.0 (0.9, 1.1)	16.6	3.4
DIC <sup>d</sup> without blood transfusion <sup>e</sup>	170,644	19.4 (18.6, 20.3)	951	0.6 (0.5, 0.6)	12.2	2.8
Hysterectomy	73,178	8.3 (8.1, 8.6)	780	1.1 (0.9, 1.2)	3.9	1.3
Eclampsia	72,025	8.2 (7.9, 8.5)	230	0.3 (0.2, 0.4)	0.1	0.0
Acute respiratory distress syndrome	46,070	5.2 (5.1, 5.4)	2,401	5.2 (4.7, 5.7)	12.0	5.2
Pulmonary edema/acute congestive heart failure	42,256	4.8 (4.6, 5.0)	372	0.9 (0.7, 1.1)	-0.6	-0.3

Mechanical ventilation	40,320	4.6 (4.4, 4.7)	3,351	8.3 (7.7, 9.0)	49.2	23.0
Both DIC <sup>d</sup> & blood transfusion <sup>e</sup>	39,056	4.4 (4.2, 4.7)	1078	2.8 (2.4, 3.1)	14.0	6.6
Acute renal failure	35,409	4.0 (3.9, 4.2)	1,212	3.4 (3.0, 3.9)	4.2	2.1
Sepsis	33,403	3.8 (3.6, 4.0)	976	2.9 (2.5, 3.4)	9.2	4.7
Cerebrovascular disorders	28,715	3.3 (3.2, 3.4)	968	3.4 (2.9, 3.9)	12.2	6.8
Severe anesthetic complications	22,079	2.5 (2.4, 2.7)	214	1.0 (0.7, 1.3)	1.8	1.1
Shock	20,290	2.3 (2.2, 2.4)	1,027	5.1 (4.4, 5.7)	1.4	0.9
Thromboembolism, pulmonary embolism	13,866	1.6 (1.5, 1.7)	528	3.8 (3.1, 4.6)	5.0	4.0
Heart failure during surgery or procedure	10,155	1.2 (1.1, 1.2)	135	1.3 (0.8, 1.8)	-0.2	-0.2
Sickle cell crisis	8,360	1.0 (0.9, 1.0)	68	0.8 (0.4, 1.2)	0.7	0.7
Cardiac arrest	5,347	0.6 (0.6, 0.7)	1,952	36.5 (33.6, 39.5)	25.0	32.1
Restoration of cardiac rhythm	5,220	0.6 (0.6, 0.6)	1,932	37.1 (34.0, 40.1)	25.2	32.6
Amniotic fluid embolism	3,858	0.4 (0.4, 0.5)	612	15.9 (13.3, 18.5)	3.1	4.6
Tracheostomy	2,104	0.2 (0.2, 0.3)	260	12.3 (9.3, 15.4)	-2.6	-5.3
Acute myocardial infarction	1,633	0.2 (0.2, 0.2)	134	8.2 (5.2, 11.2)	0.2	0.4
Aneurysm	1,077	0.1 (0.1, 0.1)	51	4.8 (2.0, 7.5)	0.8	2.2

<sup>a</sup> Population attributable fraction (PAF) calculated adjusting for other SMM indicators in this table. PAFs for all SMM indicators were

471 calculated using the formula  $p_d$  ((RR-1)/RR) where  $p_d$  is the proportion with the indicator among all hospital discharge records with

- 473 specific indicator was obtained from log-linear models, adjusting for year, payer, age, race, hospital region, hospital location (urban,
- 474 rural and teaching), and all other SMM indicators.
- 475 <sup>b</sup> Signal-to-noise ratio (SNR) is the selection criterion used to select the indicator that would maximize the ratio of the expected
- 476 number of SMM cases detected (signal) to the increase in the standard deviation of the cumulative sum of indicators (noise).
- 477 <sup>c</sup> Weighted count (n).
- 478 <sup>d</sup> Other abbreviations: 95% CI: 95% confidence interval. HELLP syndrome: hemolysis, elevated liver enzymes, and low platelet
- 479 count. DIC: disseminated intravascular coagulation.
- 480 <sup>e</sup> Recoded indicator
- 481 NOTE: The total number of indicators presented in this table is 25. This includes the 21 current CDC SMM indicators and four
- 482 recoded indicators.

### 483 Table 2. Results of the hierarchical population attributable fraction (hPAF) approach for

#### 484 severe maternal morbidity indicator selection, with the selection iteration (k) of each

### 485 indicator, the cumulative hPAF, and the signal-to-noise ratio (SNR) selection criterion at

#### 486 iteration of selection.

<b>Indicator</b> <sup>a</sup>	k <sup>b</sup>	hPAF <sup>c</sup>	Cumulative hPAF <sup>d</sup>	SNR <sup>e</sup>
		%	%	
Restoration of cardiac rhythm	1	25.2	25.2	32.6
Cardiac arrest	2	14.4	39.5	69.4
Mechanical ventilation	3	29.4	69.0	23.0
Tracheostomy	4	0.6	69.6	51.0
Amniotic fluid embolism	5	1.4	70.9	28.7
Aneurysm	6	0.3	71.2	13.3
Acute respiratory distress syndrome	7	2.3	73.6	5.3
Acute myocardial infarction	8	0.1	73.7	6.5
Shock	9	1.0	74.7	4.0
Thromboembolism, pulmonary embolism	10	0.8	75.5	3.9
Cerebrovascular disorders	11	1.3	76.8	3.2
Sepsis	12	1.0	77.8	2.6
Both DIC <sup>f</sup> & blood transfusion	13	1.0	78.8	2.6
Acute renal failure	14	0.7	79.5	2.5
Hysterectomy	15	0.6	80.1	1.0
Sickle cell crisis	16	0.1	80.2	1.0
Heart failure during surgery or procedure	17	0.1	80.3	0.9
Severe anesthetic complications	18	0.1	80.4	0.7

Pulmonary edema/acute congestive heart	19	0.2	80.6	0.7
failure				
DIC without blood transfusion	20	0.3	80.9	0.2
Blood transfusion without DIC <sup>f</sup>	21	0.7	81.6	0.2
Severe pre-eclampsia, HELLP <sup>f</sup> syndrome,	22	0.5	82.1	0.1
or eclampsia				

- <sup>a</sup> Three of the 21 current SMM indicators were excluded from this analysis, while four recoded
  indicators were included.
- <sup>489</sup> <sup>b</sup> The order of the indicators is based on the hierarchical, iterative process to determine the
- 490 ranking of indicators. The indicator with the highest signal-to-noise ratio was selected at each
- 491 iteration. The selected indicator is mutually exclusive of the remaining indicators, regardless of
- 492 whether the hospitalization included other co-occurring indicators.
- 493 <sup>c</sup> The hierarchical population attributable fraction (hPAF) value is displayed for an indicator after
- 494 previously selected indicators were made mutually exclusive. It is calculated controlling for year,
- 495 payer, age, race, hospital region, and hospital location/teaching status and for all remaining (in
- 496 hierarchical order) indicators.
- <sup>d</sup> The cumulative hPAF is calculated as the sum of hPAF for the individual indicator and those
  above in ranking.
- <sup>e</sup> Signal-to-noise ratio (SNR) is the selection criterion used to select the indicator that would
- 500 maximize the ratio of the expected number of SMM cases detected (signal) to the increase in the
- 501 standard deviation of the cumulative sum of indicators (noise).
- <sup>f</sup> Other abbreviations: DIC: disseminated intravascular coagulation. HELLP syndrome:
- 503 hemolysis, elevated liver enzymes, and a low platelet count.

504 Table 3. Observed and predicted prevalences for years 2017–2019 per 10,000 deliveries of the 15 highest ranked severe maternal

505 morbidity (SMM) indicators for in-hospital mortality, Nationwide Inpatient Sample (weighted sample = 11,001,554, unweighted

506 **sample = 2,200,312).** 

		2017			2018			2019		
Ra	Indicator	Observe	Predicted	Differen	Observ	Predicted	Differen	Observ	Predicted	Differen
nk		$\mathbf{d}^{\mathrm{a}}$	(95% CI) <sup>b</sup>	ce <sup>c</sup>	ed	(95% CI) <sup>b</sup>		ed	(95% CI) <sup>b</sup>	ce <sup>c</sup>
1	Restoration	0.85	0.65 (0.46,0.91)	0.20	0.95	0.63 (0.41,0.95)	0.32	0.99	0.61 (0.38, 0.99)	0.38
	of cardiac									
	rhythm									
2	Cardiac	0.93	0.88 (0.63,1.23)	0.05	1.21	0.91 (0.61,1.36)	0.30	1.05	0.93 (0.58, 1.50)	0.12
	arrest									
3	Mechanical	4.85	5.05 (4.41,5.77)	-0.20	5.21	4.98 (4.24,5.86)	0.23	4.74	4.92 (4.07, 5.95)	-0.18
	ventilation									
4	Tracheostom	0.18	0.26 (0.14,0.47)	-0.08	0.23	0.26 (0.12,0.54)	-0.03	0.24	0.26 (0.11, 0.61)	-0.02
	У									
5	Amniotic	0.62	0.36 (0.23,0.55)	0.26	0.62	0.34 (0.21,0.58)	0.28	0.64	0.33 (0.18, 0.60)	0.31
	fluid									
	embolism									
6	Aneurysm	0.34	0.47 (0.27,0.81)	-0.13	0.41	0.55 (0.29,1.06)	-0.14	0.38	0.64 (0.30, 1.39)	-0.26

7	Acute	9.21	8.59 (7.66,9.62)	0.62	10.25	8.78	1.47	10.14	8.97 (7.62,	1.17
	respiratory					(7.65,10.08)			10.56)	
	distress									
	syndrome									
8	Acute	0.31	0.17 (0.09,0.32)	0.14	0.37	0.16 (0.08,0.34)	0.21	0.49	0.16 (0.07, 0.37)	0.33
	myocardial									
	infarction									
9	Shock	5.55	6.15 (5.33,7.09)	-0.60	6.84	6.88 (5.79,8.18)	-0.04	6.92	7.70 (6.29, 9.43)	-0.78
10	Thromboem	3.02	2.26 (1.84,2.77)	0.76	3.62	2.31 (1.80,2.96)	1.31	2.99	2.37 (1.77, 3.16)	0.62
	bolism,									
	pulmonary									
	embolism									
11	Cerebrovasc	2.82	3.77 (3.21,4.43)	-0.95	3.40	3.81 (3.14,4.62)	-0.41	3.50	3.84 (3.06, 4.82)	-0.34
	ular									
	disorders									
12	Both DIC &	4.90	6.45 (5.71,7.29)	-1.55	4.81	6.48 (5.59,7.51)	-1.67	4.66	6.50 (5.46, 7.74)	-1.84
	blood									
	transfusion									
13	Acute renal	11.47	10.29	1.18	13.04	11.14	1.90	15.27	12.05 (10.15,	3.22

	failure		(9.12,11.61)			(9.63,12.89)			14.31)	
14	Sepsis	9.37	9.45	-0.08	10.55	10.80	-0.25	11.14	12.33 (10.06,	-1.19
			(8.20,10.90)			(9.09,12.84)			15.10)	
15	Hysterectom	11.65	12.63	-0.98	12.67	13.28	-0.61	12.53	13.97 (12.03,	-1.44
	у		(11.39,14.01)			(11.71,15.07)			16.23)	
	Top 15	46.62	45.83	0.79	52.40	48.20	4.20	54.63	50.69 (46.24,	3.94
	ranked SMM		(43.02,48.81)			(44.60,52.08)			55.57)	
	indicators									
	(cumulative)									

<sup>a</sup> According to the hierarchical population attributable fraction approach in the ranked SMM index for in-hospital mortality.

<sup>b</sup>Predictions and 95% confidence intervals were estimated based on logistic regression models using observed data from 2010 to 2015,

509 accounting for the complex sample design of the Healthcare Cost and Utilization Project National Inpatient Sample.

510 <sup>c</sup> Difference calculated by subtraction: Observed – Predicted. A positive number indicates the observed prevalence was greater than the

511 predicted prevalence. A negative number indicates the predicted prevalence was greater than the observed. Rounding occurred.

## 512 Figure

- 513 Fig 1. Prevalence of severe maternal morbidity (SMM) per 10,000 delivery hospitalizations
- 514 for (1) all 21 SMM indicators, (2) 20 SMM indicators (excluding blood transfusion), (3)
- 515 blood transfusion alone, and (4) the top 15 ranked SMM indicators that identify the most
- 516 in-hospital mortality, NIS, 1993–2019.



The blue, dotted line represents the 21 current SMM indicators developed by the Centers for Disease Control and Prevention (CDC). The green, dashed line represents the current indicator for blood transfusion alone. The red, solid line represents 20 SMM indicators (excluding blood transfusion). The purple dashed line represents the top 15 ranked SMM indicators that identify the most in-hospital mortality. Shaded areas represent the 95% confidence intervals for the regression-based SMM prevalence predictions, using 2010–2015 (ICD-9 coding) data, in 2017– 2019 (ICD-10 coding). Interval colors correspond to the respective line colors. Data from the last

- 525 quarter of 2015 and for the year 2016 were omitted because of changes in coding practices
- 526 during the first year after ICD-10 coding implementation.

# 528 Supporting information

- 529 S1 Appendix. S1 Appendix. The signal to noise ratio: formula for calculation.
- 530 S1 Table. Characteristics of study population, Nationwide Inpatient Sample, 1993–2015
- 531 (weighted sample = 87,864,173, unweighted sample = 18,198,934).